Brief: Lantern Pharma Leverages AI Platform, RADR, To Develop Breakthrough ADCS In Collaboration With Bielefeld University
08/06/2023 15:02
June 8 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA LEVERAGES AI PLATFORM, RADR®, TO DEVELOP
BREAKTHROUGH ANTIBODY DRUG CONJUGATES (ADCS) IN COLLABORATION
WITH BIELEFELD UNIVERSITY
* LANTERN PHARMA - CRYPTOPHYCIN-ANTIBODY DRUG CONJUGATES
WILL BE
TESTED ACROSS MULTIPLE CANCER CELL LINES AND INITIAL RESULTS ARE
EXPECTED DURING 2023
Source text for Eikon: ID:nBwc3Yg0Na
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview